Leading Researcher, Department of Radiation Diagnostics; A.M. Granov Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochniy pos., 197758, Russia; Physician-Radiologist, Department of Radioisotope Positron Emission Tomography; A.M. Granov Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochniy pos., 197758, Russia.
Researcher, Laboratory of Radiation Hygiene of Medical Facilities; Saint Petersburg Research Institute of Radiation Hygiene named after Professor P.V. Ramzaev, 8 Mira St., Saint Petersburg, 197101, Russia; Researcher; A.M. Granov Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochniy pos., 197758, Russia; Associate Professor, Department of Nuclear Medicine and Radiation Technologies, Almazov National Medical Research Centre, Ministry of Health of the Russian Federation, 2 Akkuratova St., Saint Petersburg, 197341, Russia.
Sovrem Tekhnologii Med. 2021;13(3):15-23. doi: 10.17691/stm2021.13.3.02. Epub 2021 Jun 28.
was to estimate the accuracy of standardized uptake values of F-fluorodeoxyglucose (F-FDG) in lung lesions during positron emission tomography combined with computed tomography (PET/CT) imaging, based on phantom studies performed for different PET/CT scanners.
The analysis of the PET/CT with F-FDG data was performed for 86 patients newly diagnosed with the lung lesions: malignant tumors (n=37), benign tumors and inflammatory diseases (n=49). The criteria for inclusion in the study were developed considering the recommendations of the Fleischner Society (2017). The characteristics of the lesions on CT met the following requirements: a round shape or close to it; total size of 8 to 30 mm; solid or subsolid structure (with the exception of lesion with ground-glass opacity); a solid part size of ≥8 mm. All the patients had no signs of pleurisy, lymphadenopathy, or cancer history. PET/CT imaging with F-FDG was performed with three scanners: Discovery 690 (General Electric, USA), Biograph mCT 128 (Siemens, Germany), and Biograph mCT 40 (Siemens); the preparation of patients prior to the scan was standardized. To determine the reference accumulation of a radiopharmaceutical in the pathological lesion, four scans of a specialized NEMA IEC PET Body Phantom Set (USA) were performed for each scanner. For each unit, the recovery coefficients (RCs) of radioactivity, maximum and recovered (corrected) standardized uptake values (SUVs) were determined. Statistical relationship between the size of lesions, SUV and SUV was evaluated. Data processing was performed using MedCalc v. 19.2.0 software.
During the phantom study, the underestimation of the radioactivity was determined in the spheres with the diameters of 10 and 13 mm, overestimation was observed in the sphere with the diameter of 28 mm. Both underestimation and overestimation of radioactivity were determined for the spheres with a diameter of 17 and 22 mm.SUV differed from the reference values for 85 patients (98.8%). The underestimation of these values was found for 63 patients (73.2%) due to the partial volume effect. The greatest underestimation was observed for the patients with 8 mm diameter lesions. Depending on the scanner, the underestimation of the SUV in these patients reached up to 54-73%. For 9 patients (25%) with malignant tumors of 9-12 mm, the utility of RC made it possible to avoid false negative results. For the lesions with a diameter of 30 mm, an overestimation of SUV up to 22% was determined due to the negative influence of the reconstruction algorithms.
The use of RC eliminates the influence of the partial volume effect and reconstruction methods on the accuracy of estimating the SUV in lung lesions, which ensures reproducibility, increase in the information content of the method, as well as the comparability of the results of PET/CT with F-FDG obtained on the different models of PET/CT units with different technological characteristics.
基于不同 PET/CT 扫描仪的体模研究,评估正电子发射断层扫描(PET)与计算机断层扫描(CT)联合成像中肺病变氟-18 脱氧葡萄糖(F-FDG)标准化摄取值(SUV)的准确性。
对新诊断为肺病变的 86 例患者进行了 F-FDG PET/CT 数据分析:恶性肿瘤(n=37)、良性肿瘤和炎性疾病(n=49)。考虑到 Fleischner 学会(2017 年)的建议,制定了纳入研究的标准。CT 上病变的特征符合以下要求:圆形或近似圆形;总直径为 8-30mm;实体或亚实性结构(磨玻璃密度病变除外);实体部分直径≥8mm。所有患者均无胸膜炎、淋巴结病或癌症病史。所有患者均使用三种扫描仪进行 F-FDG PET/CT 成像:Discovery 690(美国通用电气公司)、Biograph mCT 128(德国西门子公司)和 Biograph mCT 40(德国西门子公司);扫描前患者的准备工作标准化。为了确定放射性药物在病理性病变中的参考摄取量,每个扫描仪对专门的 NEMA IEC PET 体模集(美国)进行了 4 次扫描。针对每个单位,确定了放射性活度的恢复系数(RCs)、最大和恢复(校正)标准化摄取值(SUV)。评估了病变大小、SUV 和 SUV 之间的统计关系。数据处理使用 MedCalc v. 19.2.0 软件进行。
在体模研究中,直径为 10mm 和 13mm 的球体中放射性活度被低估,直径为 28mm 的球体中放射性活度被高估。直径为 17mm 和 22mm 的球体中,放射性活度被低估和高估。SUV 与 85 名患者(98.8%)的参考值不同。由于部分容积效应,63 名患者(73.2%)的这些值被低估。直径为 8mm 的病变患者的低估最为明显。根据扫描仪的不同,这些患者的 SUV 低估可达 54-73%。对于 9 名(25%)直径为 9-12mm 的恶性肿瘤患者,RC 的使用可以避免假阴性结果。对于直径为 30mm 的病变,由于重建算法的负面影响,SUV 被高估了 22%。
RC 可消除部分容积效应和重建方法对肺病变 SUV 估计准确性的影响,从而确保重复性、提高方法的信息量,并确保在不同技术特征的不同型号的 PET/CT 设备上获得的 F-FDG PET/CT 结果的可比性。